Notch4 inhibition reduces migration and invasion and enhances sensitivity to docetaxel by inhibiting Akt/fascin in pancreatic cancer cells

Qian,Cui‑Juan; Chen,Yi‑Yi; Zhang,Xin; Liu,Fu‑Qiang; Yue,Ting‑Ting; Ye,Bei; Yao,Jun

doi:10.3892/ol.2016.5097

Notch4 inhibition reduces migration and invasion and enhances sensitivity to docetaxel by inhibiting Akt/fascin in pancreatic cancer cells

Authors:
- Cui‑Juan Qian
- Yi‑Yi Chen
- Xin Zhang
- Fu‑Qiang Liu
- Ting‑Ting Yue
- Bei Ye
- Jun Yao
View Affiliations

Affiliations: Institute of Tumor, School of Medicine, Taizhou University, Taizhou, Zhejiang 318000, P.R. China, Department of Gastroenterology, Taizhou University Affiliated Taizhou Municipal Hospital, Taizhou, Zhejiang 318000, P.R. China
Published online on: September 7, 2016 https://doi.org/10.3892/ol.2016.5097
Pages: 3499-3505

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Overexpression of Notch4 is associated with a variety of tumor types. Only sparse information exists on Notch4 expression in pancreatic cancer (PC). The present study demonstrated that Notch4 expression was significantly upregulated in PC cell lines compared with a non‑transformed pancreatic epithelial cell line, HPDE6c‑7. To investigate the possible role of Notch4 in PC cells, an RNA interference approach was used to silence Notch4 expression. The results revealed that small interfering RNA (siRNA) targeting Notch4 significantly impeded the viability, migration and invasion abilities of PC cells in vitro. Downregulation of Notch4 with siRNA sensitized cells to the action of docetaxel. Furthermore, Notch4 downregulation enhanced the inhibition of Akt activation and the fascin expression induced by docetaxel in PC cells. Together, these data provide insight into the function of Notch4 and suggest that Notch4 may represent a new potential target for gene therapy in PC.

View Figures

View References

1	Teague A, Lim KH and Wang-Gillam A: Advanced pancreatic adenocarcinoma: A review of current treatment strategies and developing therapies. Ther Adv Med Oncol. 7:68–84. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ryan DP, Hong TS and Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014. View Article : Google Scholar : PubMed/NCBI
3	Yeo TP: Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 42:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
4	He XY and Yuan YZ: Advances in pancreatic cancer research: Moving towards early detection. World J Gastroenterol. 20:11241–11248. 2014. View Article : Google Scholar : PubMed/NCBI
5	Yilmaz M and Christofori G: Mechanisms of motility in metastasizing cells. Mol Cancer Res. 8:629–642. 2010. View Article : Google Scholar : PubMed/NCBI
6	Qian C, Liu F, Ye B, Zhang X, Liang Y and Yao J: Notch4 promotes pancreatic cancer growth through activation of Wnt1/β-catenin signaling. Mol Cell Biochem. 401:165–174. 2015. View Article : Google Scholar : PubMed/NCBI
7	Naik S, MacFarlane M and Sarin A: Notch4 signaling confers susceptibility to TRAIL induced apoptosis in breast cancer cells. J Cell Biochem. 116:1371–1380. 2015. View Article : Google Scholar : PubMed/NCBI
8	Ahn S, Hyeon J and Park CK: Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 12:286–294. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kim SH and Singh SV: The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate. Breast Cancer Res Treat. 149:681–692. 2015. View Article : Google Scholar : PubMed/NCBI
10	Manning BD and Cantley LC: AKT/PKB signaling: Navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
11	Stegeman H, Span PN, Kaanders JH and Bussink J: Improving chemoradiation efficacy by PI3-K/AKT inhibition. Cancer Treat Rev. 40:1182–1191. 2014. View Article : Google Scholar : PubMed/NCBI
12	Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, McCubrey JA, Travali S and Libra M: Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol. 40:639–644. 2012.PubMed/NCBI
13	Brown KK, Montaser-Kouhsari L, Beck AH and Toker A: MERIT40 is an Akt substrate that promotes resolution of DNA damage induced by chemotherapy. Cell Rep. 11:1358–1366. 2015. View Article : Google Scholar : PubMed/NCBI
14	Ramakrishnan G, Davaakhuu G, Chung WC, Zhu H, Rana A, Filipovic A, Green AR, Atfi A, Pannuti A, Miele L and Tzivion G: AKT and 14-3-3 regulate Notch4 nuclear localization. Sci Rep. 5:87822015. View Article : Google Scholar : PubMed/NCBI
15	Zhao X, Gao S, Ren H, Sun W, Zhang H, Sun J, Yang S and Hao J: Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res. 74:2455–2464. 2014. View Article : Google Scholar : PubMed/NCBI
16	Sheppard K, Kinross KM, Solomon B, Pearson RB and Phillips WA: Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 17:69–95. 2012. View Article : Google Scholar : PubMed/NCBI
17	Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW, Wang Z, Fan J, Dai Z and Zhou J: CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 358:124–135. 2015. View Article : Google Scholar : PubMed/NCBI
18	Booth AK and Gutierrez-Hartmann A: Signaling pathways regulating pituitary lactotrope homeostasis and tumorigenesis. Adv Exp Med Biol. 846:37–59. 2015. View Article : Google Scholar : PubMed/NCBI
19	Chen W, Zhang H, Wang J, Cao G, Dong Z, Su H, Zhou X and Zhang S: Lentiviral-mediated gene silencing of Notch-4 inhibits in vitro proliferation and perineural invasion of ACC-M cells. Oncol Rep. 29:1797–1804. 2013.PubMed/NCBI
20	Nagamatsu I, Onishi H, Matsushita S, Kubo M, Kai M, Imaizumi A, Nakano K, Hattori M, Oda Y, Tanaka M and Katano M: NOTCH4 is a potential therapeutic target for triple-negative breast cancer. Anticancer Res. 34:69–80. 2014.PubMed/NCBI
21	Singh D, Upadhyay G, Srivastava RK and Shankar S: Recent advances in pancreatic cancer: Biology, treatment, and prevention. Biochim Biophys Acta. 1856:13–27. 2015.PubMed/NCBI
22	Damaskos C, Karatzas T, Kostakis ID, Nikolidakis L, Kostakis A and Kouraklis G: Nuclear receptors in pancreatic tumor cells. Anticancer Res. 34:6897–6911. 2014.PubMed/NCBI
23	Tang SC and Chen YC: Novel therapeutic targets for pancreatic cancer. World J Gastroenterol. 20:10825–10844. 2014. View Article : Google Scholar : PubMed/NCBI
24	Mann CD, Bastianpillai C, Neal CP, Masood MM, Jones DJ, Teichert F, Singh R, Karpova E, Berry DP and Manson MM: Notch3 and HEY-1 as prognostic biomarkers in pancreatic adenocarcinoma. PLoS One. 7:e511192012. View Article : Google Scholar : PubMed/NCBI
25	Ding LC, She L, Zheng DL, Huang QL, Wang JF, Zheng FF and Lu YG: Notch-4 contributes to the metastasis of salivary adenoid cystic carcinoma. Oncol Rep. 24:363–368. 2010.PubMed/NCBI
26	Jakate AS, Einhaus CM, DeAnglis AP, Retzinger GS and Desai PB: Preparation, characterization, and preliminary application of fibrinogen-coated olive oil droplets for the targeted delivery of docetaxel to solid malignancies. Cancer Res. 63:7314–7320. 2003.PubMed/NCBI
27	Iqbal S, Lenz HJ, Gandara DR, Shibata SI, Groshen S, Synold TW and Newman EM: A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 72:85–91. 2013. View Article : Google Scholar : PubMed/NCBI
28	Salazar R, Morales S, Gil-Martín M, Aguirre E, Oaknin A, Garcia M, Callies S, Wickremsinhe ER, Benhadji KA and Llombart A: Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 73:1205–1215. 2014. View Article : Google Scholar : PubMed/NCBI
29	Zu S, Ma W, Xiao P, Cui Y, Ma T, Zhou C and Zhang H: Evaluation of docetaxel-sensitive and docetaxel-resistant proteomes in PC-3 cells. Urol Int. 95:114–119. 2015. View Article : Google Scholar : PubMed/NCBI
30	Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, et al: Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer. 112:1340–1348. 2015. View Article : Google Scholar : PubMed/NCBI
31	Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, Wojewoda C, Miele L and Sarkar FH: Downregulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem. 112:78–88. 2011. View Article : Google Scholar : PubMed/NCBI
32	Hour TC, Chung SD, Kang WY, Lin YC, Chuang SJ, Huang AM, Wu WJ, Huang SP, Huang CY and Pu YS: EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol. 89:591–605. 2015. View Article : Google Scholar : PubMed/NCBI
33	Sonego M, Gajendra S, Parsons M, Ma Y, Hobbs C, Zentar MP, Williams G, Machesky LM, Doherty P and Lalli G: Fascin regulates the migration of subventricular zone-derived neuroblasts in the postnatal brain. J Neurosci. 33:12171–12185. 2013. View Article : Google Scholar : PubMed/NCBI
34	Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan A, Al-Mohanna F, Barnawi R, Tulbah A, Al-Tweigeri T, Ajarim D and Al-Alwan M: Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway. Br J Cancer. 111:1552–1561. 2014. View Article : Google Scholar : PubMed/NCBI